{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:34:35Z","timestamp":1790937275593,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,27]]},"DOI":"10.1097\/tp.0b013e318222c9c6","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T11:57:38Z","timestamp":1307102258000},"page":"176-182","source":"Crossref","is-referenced-by-count":47,"title":["Antibody-Mediated Rejection After Alemtuzumab Induction: Incidence, Risk Factors, and Predictors of Poor Outcome"],"prefix":"10.1097","volume":"92","author":[{"given":"Michelle","family":"Willicombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Galliford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Mclean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Dorling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony N.","family":"Warrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry H.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom D.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1034\/j.1600-6143.2003.00072.x","article-title":"Antibody-mediated rejection criteria\u2014An addition to the Banff 97 classification of renal allograft rejection.","volume":"3","author":"Racusen","year":"2003","journal-title":"Am J Transplant"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","article-title":"Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups.","volume":"10","author":"Sis","year":"2010","journal-title":"Am J Transplant"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1600-6143.2009.02694.x","article-title":"Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches.","volume":"9","author":"Reeve","year":"2009","journal-title":"Am J Transplant"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/00007890-199910270-00023","article-title":"Features of acute rejection that increase risk for chronic rejection.","volume":"68","author":"Humar","year":"1999","journal-title":"Transplantation"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1600-6143.2006.01686.x","article-title":"Determinants of poor graft outcome in patients with antibody-mediated acute rejection.","volume":"7","author":"Lefaucheur","year":"2007","journal-title":"Am J Transplant"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","article-title":"Identifying specific causes of kidney allograft loss.","volume":"9","author":"El-Zoghby","year":"2009","journal-title":"Am J Transplant"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/TP.0b013e3181837626","article-title":"Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels.","volume":"86","author":"Issa","year":"2008","journal-title":"Transplantation"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/TP.0b013e3181b724a5","article-title":"Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.","volume":"88","author":"Sampaio","year":"2009","journal-title":"Transplantation"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing Registry Data.","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":"The CAMPATH-1 antigen (CDw52).","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antigens"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2009-02-203075","article-title":"Neutrophils express CD52 and exhibit complement mediated lysis in the presence of alemtuzumab.","volume":"114","author":"Ambrose","year":"2009","journal-title":"Blood"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.tp.0000191940.13473.59","article-title":"T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.","volume":"81","author":"Bloom","year":"2006","journal-title":"Transplantation"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.TP.0000071362.99021.D9","article-title":"Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).","volume":"76","author":"Kirk","year":"2003","journal-title":"Transplantation"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0140-6736(05)77739-4","article-title":"Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.","volume":"351","author":"Calne","year":"1998","journal-title":"Lancet"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00007890-199911270-00032","article-title":"Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.","volume":"68","author":"Calne","year":"1999","journal-title":"Transplantation"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study.","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1111\/j.1600-6143.2005.01123.x","article-title":"Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.","volume":"5","author":"Flechner","year":"2005","journal-title":"Am J Transplant"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial.","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation.","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trre.2008.08.004","article-title":"Antibody-mediated rejection: Treatment alternatives and outcomes.","volume":"23","author":"Singh","year":"2009","journal-title":"Transplant Rev (Orlando)"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2005.00822.x","article-title":"Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation\u2014Efficacy and safety at five years.","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1681\/ASN.2004121130","article-title":"Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.","volume":"16","author":"Hourmant","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2215\/CJN.01751105","article-title":"Sensitization after kidney transplantation.","volume":"1","author":"Akalin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-10-20210129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/01.TP.0000134398.86243.81","article-title":"Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.","volume":"78","author":"Cai","year":"2004","journal-title":"Transplantation"},{"key":"R27-10-20210129","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/TP.0b013e31816a8a6d","article-title":"Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.","volume":"85","author":"Shapiro","year":"2008","journal-title":"Transplantation"},{"key":"R28-10-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/TP.0b013e3181c3503e","article-title":"Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.","volume":"89","author":"Gill","year":"2010","journal-title":"Transplantation"},{"key":"R29-10-20210129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.TP.0000155246.52249.AC","article-title":"Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction.","volume":"79","author":"Zhang","year":"2005","journal-title":"Transplantation"},{"key":"R30-10-20210129","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/TP.0b013e3181cbac02","article-title":"Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection.","volume":"89","author":"Everly","year":"2010","journal-title":"Transplantation"},{"key":"R31-10-20210129","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"key":"R32-10-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1681\/ASN.V133779","article-title":"Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification.","volume":"13","author":"Mauiyyedi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R33-10-20210129","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1681\/ASN.V131234","article-title":"C4d deposition in acute rejection: An independent long-term prognostic factor.","volume":"13","author":"Herzenberg","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R34-10-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1681\/ASN.V131242","article-title":"Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications.","volume":"13","author":"Nickeleit","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R35-10-20210129","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/ndt\/gfk028","article-title":"Focal peritubular capillary C4d deposition in acute rejection.","volume":"21","author":"Magil","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R36-10-20210129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: Updates and future directions.","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant"},{"key":"R37-10-20210129","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1399-0012.2009.01036.x","article-title":"Differential outcomes in 3 types of acute antibody-mediated rejection.","author":"Rafiq","year":"2009","journal-title":"Clin Transplant"},{"key":"R38-10-20210129","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2007.01895.x","article-title":"Transplant glomerulopathy: Subclinical incidence and association with alloantibody.","volume":"7","author":"Gloor","year":"2007","journal-title":"Am J Transplant"},{"key":"R39-10-20210129","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1600-6143.2007.02104.x","article-title":"Transplant glomerulopathy.","volume":"8","author":"Cosio","year":"2008","journal-title":"Am J Transplant"},{"key":"R40-10-20210129","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1600-6143.2005.01050.x","article-title":"Predicting subsequent decline in kidney allograft function from early surveillance biopsies.","volume":"5","author":"Cosio","year":"2005","journal-title":"Am J Transplant"},{"key":"R41-10-20210129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1432-2277.2009.00896.x","article-title":"Treatment of symptomatic transplant glomerulopathy with rituximab.","volume":"22","author":"Rostaing","year":"2009","journal-title":"Transpl Int"},{"key":"R42-10-20210129","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.tp.0000251430.11723.b6","article-title":"Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome.","volume":"83","author":"Worthington","year":"2007","journal-title":"Transplantation"},{"key":"R43-10-20210129","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00007890-199809270-00017","article-title":"Posttransplant therapy using high-dose human immunoglobulin (IV gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.","volume":"66","author":"Jordan","year":"1998","journal-title":"Transplantation"},{"issue":"5","key":"R44-10-20210129","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action.","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"R45-10-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/sj.ki.5001870","article-title":"Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil.","volume":"71","author":"Sun","year":"2007","journal-title":"Kidney Int"},{"key":"R46-10-20210129","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"R47-10-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0b013e318222c9c6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:29:44Z","timestamp":1786044584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201107270-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,27]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318222c9c6","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,27]]}}}